DNA mismatch repair complex MutSβ promotes GAA·TTC repeat expansion in human cells

Anasheh Halabi1, Scott Ditch, Jeffrey Wang

  • 1Department of Genetics, Health Sciences Center, Louisiana State University, New Orleans, LA 70112, USA.

Insights

DNA repair mechanisms, specifically MutSβ (MSH2/MSH3), influence Friedreich ataxia (FRDA) GAA·TTC repeat expansion. Targeting MSH3, not MSH2, shows therapeutic promise for slowing FRDA repeat instability.

Area of Science:

  • Genetics
  • Molecular Biology
  • Neuroscience

Background:

  • Friedreich ataxia (FRDA) is linked to GAA·TTC repeat expansions in the FXN gene.
  • The precise role of DNA repair in GAA·TTC repeat expansion, unlike CAG·CTG repeats, remains unclear.
  • Previous work linked GAA·TTC expansion rates to transcription within the repeats.

Purpose of the Study:

  • To investigate the role of DNA repair enzymes, particularly MutSβ (MSH2/MSH3), in GAA·TTC repeat expansion in FRDA.
  • To develop and utilize a human cellular model to study FRDA repeat instability.
  • To assess the therapeutic potential of targeting specific DNA repair proteins for FRDA.

Main Methods:

  • Development of a human cellular model recapitulating FRDA DNA repeat expansion.
  • Utilizing shRNA knockdown to assess the impact of MSH2 and MSH3 on GAA·TTC expansion.
  • Employing functional assays in FRDA patient-derived fibroblasts with ectopic MSH2/MSH3 expression.

Main Results:

  • Knockdown of either MSH2 or MSH3 significantly slowed GAA·TTC repeat expansion in the cellular model.
  • Ectopic expression of MSH2 and MSH3 induced GAA·TTC repeat expansion in native FXN genes in FRDA fibroblasts.
  • MSH2's critical role in mismatch repair and cancer predisposition makes it an unattractive therapeutic target.
  • MSH3 absence/reduction is not strongly linked to cancer predisposition, suggesting its potential as a therapeutic target.

Conclusions:

  • MutSβ (MSH2/MSH3) plays a crucial role in the expansion of GAA·TTC repeats in the context of FRDA.
  • MSH3 inhibition represents a potential therapeutic strategy to mitigate GAA·TTC repeat expansion and treat FRDA.
  • Further research into MSH3's mechanism in GAA·TTC repeat expansion could lead to novel FRDA therapies.